Vanguard Group Inc. reduced its position in Zogenix, Inc. (NASDAQ:ZGNX) by 8.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 893,523 shares of the company’s stock after selling 81,425 shares during the quarter. Vanguard Group Inc. owned 3.60% of Zogenix worth $12,956,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Northern Trust Corp boosted its stake in Zogenix by 15.3% in the second quarter. Northern Trust Corp now owns 341,309 shares of the company’s stock valued at $4,949,000 after acquiring an additional 45,219 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Zogenix during the second quarter worth $231,000. Nationwide Fund Advisors raised its holdings in shares of Zogenix by 367.3% during the second quarter. Nationwide Fund Advisors now owns 87,611 shares of the company’s stock worth $1,270,000 after purchasing an additional 68,863 shares during the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Zogenix by 0.9% during the second quarter. TIAA CREF Investment Management LLC now owns 66,610 shares of the company’s stock worth $966,000 after purchasing an additional 608 shares during the last quarter. Finally, Teachers Advisors LLC raised its holdings in shares of Zogenix by 6.9% during the second quarter. Teachers Advisors LLC now owns 44,555 shares of the company’s stock worth $646,000 after purchasing an additional 2,876 shares during the last quarter. 73.43% of the stock is currently owned by institutional investors.
In other Zogenix news, major shareholder Life Sciences Maste Perceptive purchased 222,055 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was purchased at an average price of $32.83 per share, for a total transaction of $7,290,065.65. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.60% of the company’s stock.
A number of research analysts have weighed in on ZGNX shares. ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. BidaskClub lowered shares of Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Stifel Nicolaus restated a “buy” rating and set a $55.00 price target (up from $26.00) on shares of Zogenix in a research report on Friday, September 29th. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Mizuho reissued a “buy” rating and issued a $51.00 price target (up from $28.00) on shares of Zogenix in a research note on Friday, September 29th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $42.67.
Shares of Zogenix, Inc. (ZGNX) traded down $0.75 during trading hours on Wednesday, hitting $34.10. 885,285 shares of the company’s stock were exchanged, compared to its average volume of 669,923. Zogenix, Inc. has a 52 week low of $7.70 and a 52 week high of $42.60. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.23.
ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Sells 81,425 Shares of Zogenix, Inc. (ZGNX)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://ledgergazette.com/2017/12/07/vanguard-group-inc-sells-81425-shares-of-zogenix-inc-zgnx.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.